Literature DB >> 14690157

Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer--clinical associations and reasons for discrepancies.

Gunilla Chebil1, Pär-Ola Bendahl, Ingrid Idvall, Marten Fernö.   

Abstract

Estrogen (ER) and progesterone receptor (PgR) status was analysed in paraffin-embedded breast cancer material with immunohistochemical (IHC) technique and compared with corresponding analyses in cytosols (CYT). ER showed the same status (positive/negative) with both methods in 88% of the samples (352/402). The concordance was also high for PgR status (81% [321/394]). Besides values near cut-off, heterogeneity in the distribution of receptor positive and negative nuclei within a tumour sample was the main reason for discordances. Histological type, presence of sclerosis, necrosis and non-invasive cells, and technical artefacts seem to be of only limited importance for explaining discordances All patients have been treated with adjuvant tamoxifen for two years. The two subgroups, which were ER(CYT)+/ ER(IHC) + or ER(CYT)-/ER(IHC) +, both had a significantly better progression-free survival (PFS; median follow-up: almost 6 years) than the ER(CYT)-/ER(IHC)- group (p < 0.001 and p = 0.007, respectively). The remaining group, ER(CYT)+/ER(IHC)-, had an intermediate PFS. For PgR, the associations with PFS were weaker, with significantly better PFS than the PgR(CYT)-/PgR(IHC)- group being found only for the PgR(CYT) +/PgR(IHC)- group (p = 0.03).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14690157     DOI: 10.1080/02841860310004724

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  13 in total

1.  Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?

Authors:  Anna-Karin Falck; Mårten Fernö; Pär-Ola Bendahl; Lisa Rydén
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

2.  Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.

Authors:  Siker Kimbung; Anikó Kovács; Pär-Ola Bendahl; Per Malmström; Mårten Fernö; Thomas Hatschek; Ingrid Hedenfalk
Journal:  Mol Oncol       Date:  2013-10-14       Impact factor: 6.603

3.  Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

Authors:  Olivia Pagani; Shari Gelber; Edda Simoncini; Monica Castiglione-Gertsch; Karen N Price; Richard D Gelber; Stig B Holmberg; Diana Crivellari; John Collins; Jurij Lindtner; Beat Thürlimann; Martin F Fey; Elizabeth Murray; John F Forbes; Alan S Coates; Aron Goldhirsch
Journal:  Breast Cancer Res Treat       Date:  2008-10-25       Impact factor: 4.872

4.  High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.

Authors:  Rachel A Sanford; Juhee Song; Angelica M Gutierrez-Barrera; Jessica Profato; Ashley Woodson; Jennifer Keating Litton; Isabelle Bedrosian; Constance T Albarracin; Vicente Valero; Banu Arun
Journal:  Cancer       Date:  2015-08-17       Impact factor: 6.860

5.  Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

Authors:  Mervi Jumppanen; Sofia Gruvberger-Saal; Päivikki Kauraniemi; Minna Tanner; Pär-Ola Bendahl; Mikael Lundin; Morten Krogh; Pasi Kataja; Ake Borg; Mårten Fernö; Jorma Isola
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

6.  Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.

Authors:  Kristina E Aaltonen; Ann H Rosendahl; Hans Olsson; Per Malmström; Linda Hartman; Mårten Fernö
Journal:  BMC Cancer       Date:  2014-11-03       Impact factor: 4.430

7.  The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.

Authors:  Carina Strand; Martin Bak; Signe Borgquist; Gunilla Chebil; Anna-Karin Falck; Marie-Louise Fjällskog; Dorthe Grabau; Ingrid Hedenfalk; Karin Jirström; Marie Klintman; Per Malmström; Hans Olsson; Lisa Rydén; Olle Stål; Pär-Ola Bendahl; Mårten Fernö
Journal:  Springerplus       Date:  2013-03-14

8.  Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.

Authors:  Rebecca Ritte; Annekatrin Lukanova; Franco Berrino; Laure Dossus; Anne Tjønneland; Anja Olsen; Thure Filskov Overvad; Kim Overvad; Françoise Clavel-Chapelon; Agnès Fournier; Guy Fagherazzi; Sabine Rohrmann; Birgit Teucher; Heiner Boeing; Krasimira Aleksandrova; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Domenico Palli; Sabina Sieri; Salvatore Panico; Rosario Tumino; Paolo Vineis; José Ramón Quirós; Genevieve Buckland; Maria-José Sánchez; Pilar Amiano; María-Dolores Chirlaque; Eva Ardanaz; Malin Sund; Per Lenner; Bas Bueno-de-Mesquita; Carla H van Gils; Petra Hm Peeters; Sanda Krum-Hansen; Inger Torhild Gram; Eiliv Lund; Kay-Tee Khaw; Nick Wareham; Naomi E Allen; Timothy J Key; Isabelle Romieu; Sabina Rinaldi; Afshan Siddiq; David Cox; Elio Riboli; Rudolf Kaaks
Journal:  Breast Cancer Res       Date:  2012-05-14       Impact factor: 6.466

9.  The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Authors:  Gabriella Honeth; Pär-Ola Bendahl; Markus Ringnér; Lao H Saal; Sofia K Gruvberger-Saal; Kristina Lövgren; Dorthe Grabau; Mårten Fernö; Ake Borg; Cecilia Hegardt
Journal:  Breast Cancer Res       Date:  2008-06-17       Impact factor: 6.466

10.  Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study.

Authors:  Rebecca Ritte; Kaja Tikk; Annekatrin Lukanova; Anne Tjønneland; Anja Olsen; Kim Overvad; Laure Dossus; Agnès Fournier; Françoise Clavel-Chapelon; Verena Grote; Heiner Boeing; Krasimira Aleksandrova; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Domenico Palli; Franco Berrino; Amalia Mattiello; Rosario Tumino; Carlotta Sacerdote; José Ramón Quirós; Genevieve Buckland; Esther Molina-Montes; María-Dolores Chirlaque; Eva Ardanaz; Pilar Amiano; H Bas Bueno-de-Mesquita; Carla H van Gils; Petra Hm Peeters; Nick Wareham; Kay-Tee Khaw; Timothy J Key; Ruth C Travis; Elisabete Weiderpass; Vanessa Dumeaux; Eliv Lund; Malin Sund; Anne Andersson; Isabelle Romieu; Sabina Rinaldi; Paulo Vineis; Melissa A Merritt; Elio Riboli; Rudolf Kaaks
Journal:  BMC Cancer       Date:  2013-12-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.